We anticipate that this therapeutic evolution, combined with the incorporation of rapid and long-acting insulin analogs and the availability of digital tools that automate bolus insulin calculations, like GlicTM, will lead to improved glycemic control and reduced hypoglycemia events in insulin users in Brazil. The gene discussed is INS; the disease is Hypoglycemia.